Pitt and UPMC Experts Share Promising Breakthrough in COVID-19 Drug Development
IDM’s John Mellors, UPMC’s chief of infectious diseases, said the biological molecule “is small, which means it penetrates into areas of the body where a full-sized antibody may not. It’s fully human, meaning that there’s no foreign material that’s likely to be rejected by the host… and it appears to be safe.” But he added, it's too early to talk about pricing of a treatment when it’s not (tested) in humans yet.
Read full story in CUMBERLAND TIMES-NEWS
View video from Pitt/UPMC